Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eviplera Switch Study in HIV
NCT02529059Phase 4Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Nov 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1), sponsored by St Stephen's AIDS Trust. Primary endpoints: Proportion of patients experiencing grade 2-4 neuropsychiatric and CNS toxicity at 4 weeks, Median number of grade 2-4 neuropsychiatric and CNS toxicity at 4 weeks and 2 more. Started Nov 2015; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02529059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529059.